Perspective Extends Cash Runway Into 2028

The Tip Desk · November 9, 2026 · 3 min read

Cash, cash equivalents, and short-term investments were about $202 million as of September 30, 2026, and the company said the balance should fund planned clinical work into 2028.

Perspective Therapeutics (CATX), a radiopharmaceutical development company, said cash, cash equivalents, and short-term investments of about $202 million as of September 30, 2026, are expected to fund current planned clinical milestones and operational investments into 2028, later than the late-2027 horizon it had cited after the June quarter.

The balance was down from about $237 million as of June 30, 2026. The company also said it had entered a clinical trial collaboration and supply agreement with Merck in September 2026 to support potential evaluation of PSV359 in combination with Keytruda (pembrolizumab) for certain types of lung and colorectal cancers.

For the three months ended September 30, 2026, net loss was $32.4 million, or $0.27 a share, compared with a net loss of $26.0 million, or $0.35 a share, a year earlier. Weighted-average basic and diluted shares rose to 120.7 million from 74.3 million. Operating loss widened to $34.3 million from $27.9 million. Grant revenue was $20 thousand.

Research and development expenses were $26.1 million, up from $20.3 million a year earlier. General and administrative expenses were $8.3 million, compared with $7.7 million. Property and equipment, net, was $117.9 million as of September 30, 2026, versus $76.6 million at year-end 2025. Total assets were $365.7 million.

The company’s flagship program, bamzireotide navoxetan (VMT-α-NET) for SSTR2-positive neuroendocrine tumors, shifted its near-term path. In the August update, Perspective had targeted Phase 3 site activation around year-end 2026, subject to regulatory feedback. It now said it is targeting an end-of-Phase 2 meeting with the FDA in the first quarter of 2027. European orphan medicinal product designation was granted in July 2026 for gastroenteropancreatic NETs.

Cohort 4 of the VMT-α-NET dose-finding study closed for recruitment with 20 patients enrolled as of October 30, 2026. The meningioma cohort remained open, with two patients treated as of that date. Updated interim data were presented at ESMO Congress 2026 and the NANETS symposium, the company said, showing strong clinical efficacy.

Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma showed meaningful antitumor activity in monotherapy, the company said, with longer-follow-up data presented at SITC. As of October 30, 2026, 12 patients had been treated in a monotherapy cohort allowing up to a cumulative 9 mCi (333 MBq) in three treatments of 3.0 mCi every eight weeks. Five patients had been treated since the cohort reopened during the third quarter. The cohort remains open.

PSV359 in FAP-α-positive solid tumors remained at 17 patients treated across three dose cohorts as of September 30, 2026. In October 2026, the FDA granted PSV359 Fast Track Designation for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The next clinical update is planned in 2027.

Construction at the Chicago metro manufacturing site is expected to be completed in early 2027. Chief Executive Officer Thijs Spoor said the company is well-positioned to lead development of the field, citing bamzireotide data, progress in melanoma and FAP-α-positive solid tumors, and manufacturing investments.